| Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine C Pauli, BD Hopkins, D Prandi, R Shaw, T Fedrizzi, A Sboner, V Sailer, ... Cancer discovery 7 (5), 462-477, 2017 | 897 | 2017 |
| Pan-cancer alterations of the MYC oncogene and its proximal network across the cancer genome atlas FX Schaub, V Dhankani, AC Berger, M Trivedi, AB Richardson, R Shaw, ... Cell systems 6 (3), 282-300. e2, 2018 | 374 | 2018 |
| Patient derived organoids to model rare prostate cancer phenotypes L Puca, R Bareja, D Prandi, R Shaw, M Benelli, WR Karthaus, J Hess, ... Nature communications 9 (1), 2404, 2018 | 308 | 2018 |
| BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer GYL Lui, R Shaw, FX Schaub, IN Stork, KE Gurley, C Bridgwater, RL Diaz, ... EBioMedicine 60, 2020 | 32 | 2020 |
| Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer C Xu, O Nikolova, RS Basom, RM Mitchell, R Shaw, RD Moser, H Park, ... Clinical Cancer Research 24 (12), 2828-2843, 2018 | 27 | 2018 |
| Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma S Shigeta, GYL Lui, R Shaw, R Moser, KE Gurley, G Durenberger, ... Molecular cancer therapeutics 20 (4), 691-703, 2021 | 21 | 2021 |
| Stacking machine learning algorithms for biomarker-based preoperative diagnosis of a pelvic mass R Shaw, AE Lokshin, MC Miller, G Messerlian-Lambert, RG Moore Cancers 14 (5), 1291, 2022 | 9 | 2022 |
| Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in CCDC6-RET–rearranged thyroid cancer R Raman, JA Villefranc, TM Ullmann, J Thiesmeyer, V Anelli, J Yao, ... Journal of Experimental Medicine 219 (6), e20210390, 2022 | 8 | 2022 |
| Stagnation in quality of next‐generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies GW Roloff, R Shaw, TE O'Connor, F Hathaway, MW Drazer Journal of Genetic Counseling 32 (3), 744-749, 2023 | 6 | 2023 |
| A functional precision oncology approach to identify treatment strategies for myxofibrosarcoma patients C Pauli, L De Boni, JE Pauwels, Y Chen, L Planas-Paz, R Shaw, ... Molecular Cancer Research 20 (2), 244-252, 2022 | 5 | 2022 |
| Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes A Hamidi, GW Roloff, R Shaw, M Acevedo, S Smith, MW Drazer Leukemia & Lymphoma 64 (9), 1562-1565, 2023 | 3 | 2023 |
| Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy TE O’Connor, R Shaw, R Madero-Marroquin, GW Roloff Frontiers in Oncology 13, 1180439, 2023 | 2 | 2023 |
| Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplantation R Shaw, AR Haque, T Luu, TE O’Connor, A Hamidi, J Fitzsimons, B Varda, ... Frontiers in Oncology 13, 1146002, 2023 | 1 | 2023 |
| Assessing the predictive value of methicillin-resistant Staphylococcus aureus nares colonization amongst transplant recipients and patients with neutropenia R Shaw, A Zander, T Ronnie, Z Azari, A Gregorowicz, F Albarillo Open Forum Infectious Diseases, ofae408, 2024 | | 2024 |
| Multicenter analysis of COVID-19 hospitalizations and stacking machine learning algorithms for prediction of high-risk patients R Shaw, D Bassily, L Patel, T O’Connor, R Rafidi, P Formanek medRxiv, 2023.06. 20.23291685, 2023 | | 2023 |
